Vivos Therapeutics Inc.

11/04/2025 | Press release | Distributed by Public on 11/04/2025 15:58

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 4, 2025, Vivos Therapeutics, Inc. (the "Company") conducted its 2025 annual meeting of stockholders (the "Annual Meeting"). The number of shares of common stock of the Company entitled to vote at the Annual Meeting was 7,504,807 shares outstanding as of the September 8, 2025 record date (the "Voting Stock"). No other shares of the Company's capital stock were entitled to vote at the Annual Meeting.

The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was approximately 4,968,728 shares of Voting Stock, constituting a quorum. At the Annual Meeting, the Company's stockholders:

(i) elected each of R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson (collectively, the "Director Nominees") to serve as directors on the Company's Board of Directors (the "Board") for a one-year term that expires at the 2026 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their successors are elected and qualified;
(ii) approved and adopted an amendment (the "Amendment") to the Company's 2024 Omnibus Equity Incentive Plan (the "2024 Plan"); and
(iii) ratified the appointment of Baker Tilly US, LLP, the successor to Moss Adams LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

Proposal No. 1 - Election of Directors

R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson were each elected as a director to serve for a one-year term that expires at the 2026 annual meeting of stockholders or until a successor is elected and qualified or until her or his earlier death, incapacity, removal or resignation. The voting results were as follows:

Nominee Shares Voted For Shares Withheld Broker Non-Vote
R. Kirk Huntsman 2,763,108 208,971 1,996,649
Dr. Ralph Green 2,661,653 310,426 1,996,649
Anja Krammer 2,741,252 230,827 1,996,649
Mark Lindsay 2,780,996 191,083 1,996,649
Leonard Sokolow 2,700,161 271,918 1,996,649
Dr. Matthew Thompson 2,627,358 344,721 1,996,649

Proposal No. 2 - Approval of the Amendment to the Company's 2024 Omnibus Equity Incentive Plan

Approved and adopted the Amendment to the 2024 Plan. The voting results were as follows:

Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote
2,453,436 516,368 2,275 1,996,649

Proposal No. 3 - Ratification of the appointment of independent registered public accounting firm

Appointment by the Company's audit committee of Baker Tilly US, LLP, the successor to Moss Adams LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. The voting results were as follows:

Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote
4,861,139 102,827 4,762 n/a
Vivos Therapeutics Inc. published this content on November 04, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 04, 2025 at 21:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]